Ignite Creation Date:
2024-05-05 @ 5:23 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00446069
Status:
COMPLETED
Last Update Posted:
2016-08-29
First Post:
2007-03-09
Brief Title:
A Efficacy and Safety Trial of Controlled Release CR Morphine in Cancer Patients
Sponsor:
Egalet Ltd
Organization:
Egalet Ltd
Study Overview
Official Title:
A Double-blind Randomized 2-way Cross-over Phase II Efficacy Trial in Cancer Patients to Assess the Overall Efficacy Patient Preference Morphine Related Side Effect Profile and Safety of the Egalet Controlled Release Morphine Formulation 30-240 mg Once Daily Compared to MST Continus 15-120 mg Twice Daily After 2 Weeks of Treatment
Status:
COMPLETED
Status Verified Date:
2016-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to determine the effect of Egalet Morphine once daily compared to MST Continus twice daily on pain intensity and use of rescue medication for break through pain after 2 weeks of treatment in patients with pain due to cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EudraCT number 2006-006579-19 | None | None | None |